Commonground
Senior Moderator
ALBANY, N.Y. (May 9, 2025) – The New York State Department of Health is highlighting a new Centers for Disease Control and Prevention (CDC)-led report, co-authored by the Department, showing that two respiratory syncytial virus (RSV) prevention products – the maternal RSV vaccine and the long-acting monoclonal antibody nirsevimab – are effective in protecting infants from severe illness.
The paper, published in CDC's Morbidity and Mortality Weekly Report (MMWR), compared hospitalization rates in children during the 2024-2025 RSV season with earlier respiratory virus seasons and found that hospitalization rates were significantly lower for infants who received RSV prevention products. Findings from this study indicate New York is on the right path in reducing the risk of RSV hospitalizations in infants.
continued: https://health.ny.gov/press/releases/2025/2025-05-09_respiratory_syncytial_virus.htm
The paper, published in CDC's Morbidity and Mortality Weekly Report (MMWR), compared hospitalization rates in children during the 2024-2025 RSV season with earlier respiratory virus seasons and found that hospitalization rates were significantly lower for infants who received RSV prevention products. Findings from this study indicate New York is on the right path in reducing the risk of RSV hospitalizations in infants.
continued: https://health.ny.gov/press/releases/2025/2025-05-09_respiratory_syncytial_virus.htm